Healthy
Conditions
Brief summary
The purpose of this study is to evaluate the effects of stomach acid suppression by rabeprazole and BMS-986165 on how fast and complete the drug is absorbed into the body of healthy participants.
Interventions
DRUGBMS-986165
Specified dose on specified days.
DRUGRabeprazole
Specified dose on specified days.
Sponsors
Bristol-Myers Squibb
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy participant, as determined by medical history, physical examination, ECGs, and clinical laboratory determinations * Body mass index of 18.0 kilogram per meter square (kg/m\^2) to 32.0 kg/m\^2 * Normal renal function at screening as evidenced by an estimated glomerular filtration rate (GFR) greater than (\>) 80 milliliter per minute per 1.732 meter square (mL/min/1.732 m\^2)
Exclusion criteria
* Any major surgery within 4 weeks of study drug administration * Use of any prescription drugs or over-the-counter acid controllers * Positive urine screen for drugs of abuse, alcohol, or cotinine * History of allergy to BMS-986165, rabeprazole, or related compounds Other protocol inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of BMS-986165 | Day 1 and Day 9 |
| Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-T]) of BMS-986165 | Day 1 and Day 9 |
| Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF]) of BMS-986165 | Day 1 and Day 9 |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of Participants with Adverse Events (AEs) | Up to Day 12 |
| Percentage of Participants with Clinical Laboratory Values, Vital Signs, and Electrocardiograms (ECGs) | Up to Day 12 |
Countries
Netherlands
Outcome results
None listed